DOUBLE ISSUE: New in Oncology - July 8, 2026

ASCO’s long tail keeps delivering in this massive issue: RCC immunotherapy, myeloma CAR-T, AML triplets, PDAC combinations, bladder ADCs, CRC bispecifics, and KRAS T-cell targeting—plus 14 new trials.